Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 5Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Genitourinary 1Breast 1

Conditions

Breast Neoplasms 20Carcinoma, Renal Cell 17Neoplasm Metastasis 15Carcinoma, Non-Small-Cell Lung 13Neoplasms 11Neuroendocrine Tumors 10Recurrence 8Lung Neoplasms 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Prostatic Neoplasms 5Multiple Myeloma 5Lymphoma, Mantle-Cell 5Lymphoma 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Brain Neoplasms 5Triple Negative Breast Neoplasms 4Lymphoma, Non-Hodgkin 4Lymphoma, Follicular 4Hodgkin Disease 4Head and Neck Neoplasms 4Glioblastoma 4Waldenstrom Macroglobulinemia 3Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Cisplatin 18IFL protocol 17Folfox protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × Everolimus × Clear all
NCT02890069 2023-01-11

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Novartis

Phase 1 Completed
298 enrolled
BreastGastrointestinalGenitourinaryThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT01154335 2022-05-03

Everolimus and OSI-906 for Patients With Refractory Metastatic Colorectal Cancer

SCRI Development Innovations, LLC

Phase 1 Completed
18 enrolled 9 charts
Gastrointestinal

Colorectal Neoplasms

NCT00478634 2012-11-02

A Phase 1 Study Investigating the Combination of RAD001, Cetuximab and Irinotecan as Second-line Therapy After FOLFOX (or XELOX) Plus Bevacizumab in Patients With Metastatic Colorectal Cancer

Novartis

Phase 1 Completed
19 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡